Preclinical tests shows agent stops 'slippery' proteins from binding, causing Ewing sarcoma

(Georgetown University Medical Center) Continuous infusion of a novel agent not only halted the progression of Ewing sarcoma in rats, while some tumors also regressed to the point that cancer cells could not be detected microscopically. Researchers say the study provides preclinical evidence necessary to initiate a clinical trial.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news